ArticleMaterials (Basel, Switzerland)2023
Physicochemical Properties of Gold Nanoparticles for Skin Care Creams.
Article in Materials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Nanotechnology-based drug formulation and delivery systems for skin medical aesthetic dermatology: mechanisms, applications, and safety.Frontiers in pharmacology · 2026Review
- Advantages and therapeutic applications of different semisolids as vehicles for nano-based systems.Therapeutic delivery · 2025Review
- Studying the Effect of Reducing Agents on the Properties of Gold Nanoparticles and Their Integration into Hyaluronic Acid Hydrogels.Molecules (Basel, Switzerland) · 2024Article
- Romanian Wild-GrowingPlants (Basel, Switzerland) · 2024Article
- The Preparation of Silver and Gold Nanoparticles in Hyaluronic Acid and the Influence of Low-Pressure Plasma Treatment on Their Physicochemical and Microbiological Properties.International journal of molecular sciences · 2023Article
- Recovery Study of Gold Nanoparticle Markers from Lateral Flow Immunoassays.Materials (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Gold nanoparticles (AuNPs) have now been used in skin care creams for several years, with marketed anti-aging, moisturizing, and regenerative properties. Information on the harmful effects of these nanoparticles is lacking, a concern for the use of AuNPs as cosmetic ingredients. Testing AuNPs without the medium of a cosmetic product is a typical method for obtaining this information, which is mainly dependent on their size, shape, surface charge, and dose. As these properties depend on the surrounding medium, nanoparticles should be characterized in a skin cream without extraction from the cream's complex medium as it may alter their physicochemical properties. The current study compares the sizes, morphology, and surface changes of produced dried AuNPs with a polyvinylpyrrolidone (PVP) stabilizer and AuNPs embedded in a cosmetic cream using a variety of characterization techniques (TEM, SEM, DLS, zeta potential, BET, UV-vis). The results show no observable differences in their shapes and sizes (spherical and irregular, average size of 28 nm) while their surface charges changed in the cream, indicating no major modification of their primary sizes, morphology, and the corresponding functional properties. They were present as individually dispersed nanoparticles and as groups or clusters of physically separated primary nanoparticles in both dry form and cream medium, showing suitable stability. Examination of AuNPs in a cosmetic cream is challenging due to the required conditions of various characterization techniques but necessary for obtaining a clear understanding of the AuNPs' properties in cosmetic products as the surrounding medium is a critical factor for determining their beneficial or harmful effects in cosmetic products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.